@Southoz In most instances this may be correct however, when the patient cohort is one defined as unresponsive to best available treatment and they are the patient group of whom are considered the most severe and highest risk of dying. The FDA will look at this differently, especially within the paediatric cohort, as we know RCT’s have ethical consequences hence the single arm trial and it has demonstrated the best response in terms of survival that any other medication has in such a severe grade of disease. So yes, the survival data is the cornerstone of the resubmission in conjunction with the potency assays demonstrating a relationship between drug MOI and response. This is why the FDA have performed a 10 day manufacturing inspection, have accepted the BLA resubmission and why it will be approved before or on the 2nd of august
- Forums
- ASX - By Stock
- MSB
- Ann: MSB Reports Q3 Financial Results and Operational Highlights
Ann: MSB Reports Q3 Financial Results and Operational Highlights, page-329
-
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.39 |
Change
-0.005(0.36%) |
Mkt cap ! $1.581B |
Open | High | Low | Value | Volume |
$1.40 | $1.42 | $1.38 | $2.660M | 1.906M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 6981 | $1.39 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.39 | 21773 | 19 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 72728 | 1.380 |
15 | 137703 | 1.375 |
11 | 71932 | 1.370 |
7 | 106053 | 1.365 |
10 | 406017 | 1.360 |
Price($) | Vol. | No. |
---|---|---|
1.385 | 8882 | 20 |
1.390 | 20848 | 12 |
1.395 | 105877 | 9 |
1.400 | 122666 | 26 |
1.405 | 79674 | 7 |
Last trade - 13.45pm 10/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
EL8
ELEVATE URANIUM LTD
Murray Hill, MD & CEO
Murray Hill
MD & CEO
SPONSORED BY The Market Online